| |
| HBV |Abstract Library |
 |
| |
| The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors. |
| Abstract Details |
 |
|
| |
| |
| |
|
|
| |
Circulating Pregenomic HBV RNA is Primarily Full-length in Chronic Hepatitis B Patients Undergoing Nucleos(t)ide Analogue Therapy |
|
|
|
|
| |
Clin Infect Dis. 2020 Jul 20;ciaa1015. doi: 10.1093/cid/ciaa1015. Online ahead of print.
Mark Anderson 1, Jeffery Gersch 1, Ka-Cheung Luk 1, George Dawson 1, Ivana Carey 2, Kosh Agarwal 3, Pir Shah 4, Geoffrey Dusheiko 3, Daryl Lau 5, Gavin Cloherty 1
|
| |
|
|
| |
Author information
- 1Abbott Laboratories, Abbott Diagnostics Division, Abbott Park, Illinois.
- 2King's College, London, United Kingdom.
- 3Institute of Liver Studies, King's College Hospital, London, United Kingdom.
- 4Harvard University, Boston, Massachusetts.
- 5Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
Abstract
HBV RNA is detectable in the serum of infected patients, however the RNA species has been questioned. We tested 1827 specimens using a quantitative dual-target qPCR assay and determined full-length pregenomic RNA is the primary source. These results clarify the major identity of circulating HBV RNA species.
|
|
|
|
| |
| |
|
| |
|
|
|
|
|
